CD4 and type 1 diabetes mellitus: Our study also underscores the potent immunomodulatory benefits of LRH1/NR5A2 activation on whole PBMCs of individuals with T1D, characterised by an increase in CD4+/CD25+/FoxP3+ T‐cells and Th2 cells with a concurrent decrease in Th1 cells, consistent with our previous findings in mice.19